Showing 8581-8590 of 9547 results for "".
- More Screening Won’t Solve Racial Disparities in Melanoma Outcomeshttps://practicaldermatology.com/news/more-screening-wont-solve-racial-disparities-in-melanoma-outcomes/2461894/Increased skin cancer screening in individuals with skin of color is not sufficient to address racial disparities in melanoma survival rates, according to a new study in JAMA Dermatology.
- Study: Men With Skin of Color Are More Likely to Die From Melanomahttps://practicaldermatology.com/news/study-men-with-skin-of-color-are-more-likely-to-doe-from-melanoma/2461853/Men with melanoma – and particularly men with skin of color – are more likely to die than women with melanoma, a new study in the Journal of the American Academy of Dermatology shows. "We know that men may be less likely to seek medical care than w
- Fecal Transplants Show Promise in Improving Response to Immunotherapy in Melanoma Patientshttps://practicaldermatology.com/news/fecal-transplants-show-promise-in-improving-response-to-immunotherapy-in-melanoma-patients/2461849/Fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma, according to research in Nature Medicine. Preliminar
- WCD News: Tildrakizumab Improves Wellbeing of PsO Patientshttps://practicaldermatology.com/news/wcd-news-tildrakizumab-improves-wellbeing-of-pso-patients/2461848/Ilumetri (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis, according to research reported by Almirall, S.A. (ALM) at poster at the 25th World Congress of Dermatology in Singapore. Patients taking tild
- Laura Bush Named SDPA’s Board Presidenthttps://practicaldermatology.com/news/laura-bush-named-sdpas-board-president/2461847/Georgia-based dermatology physician assistant Laura Bush is the new president of the Society of Dermatology Physician Assistant's (SDPA) Board of Directors. Bush, a DermPA with Fayette Area Dermatology in Fayetteville, Georgia, will serve a one-year term leading the nine-membe
- Nemolizumab Monotherapy Curbs Itch in Prurigo Nodularis by Week 4https://practicaldermatology.com/news/nemolizumab-monotherapy-curbs-itch-in-prurigo-nodularis-by-week-4/2461840/Nemolizumab monotherapy quickly tames itch in Prurigo Nodularis, according to a late-breaking late-breaking Phase III study presented at the 25th World Congress of Dermatology (WCD) in Singapore. Fully 19.7% of patients treated with nemolizumab monotherapy achieved an itc
- WCD News: Janssen's Oral IL-23 Blocker Shows Promise in Phase 2b PsO Studyhttps://practicaldermatology.com/news/wcd-news/2461839/Janssen’s novel oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 performed well in the Phase 2b FRONTIER 1 clinical trial of adults with moderate-to-severe plaque psoriasis (PsO), the Company reports. JNJ-2113 is a novel oral IL-23R antagonist peptide that binds w
- Biosimilar News: Coherus Launches Humira Biosimilar at $995 per Carton in U.S.https://practicaldermatology.com/news/biosimilar-news-coherus-launches-humira-biosimilar-at-995-per-carton-in-us/2461834/Coherus BioSciences, Inc’s YUSIMRY (adalimumab-aqvh) is now available for commercial sale in the United States at a list price of $995 per carton for two 40 mg/0.8 mL autoinjectors. This cost represents a discount of more than 85% to Humira (adalimumab), currently price
- TikTok Trend Watch: Browning Lotions and Summer Tanshttps://practicaldermatology.com/news/tik-tok-trend-watch-browning-lotions-and-summer-tans/2461830/Skinfluencers on social media are praising browning lotions for perfecting their summer tans. What is browning lotion? Browning lotion or tanning accelerators work with the sun's UV rays to darken your skin faster. What could go wrong?
- FDA Clears Candela's Vbeam 595 nm Pulsed Dye Laser for the Treatment of Port Wine Stains and Hemangiomas in the Pediatric Populationhttps://practicaldermatology.com/news/fda-clears-vbeam-595-nm-pulsed-dye-laser-for-the-treatment-of-port-wine-stains-and-hemangiomas-in-the-pediatric-population/2461824/The U.S Food and Drug Administration has cleared candela’s Vbeam family of 595 nm wavelength pulsed dye lasers (PDL) to treat cutaneous capillary malformations, and infantile hemangiomas (IH)/congenital hemangiomas in the pediatric population (from birth – 21 years of age).